|
Oct 1
|
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
|
|
Sep 9
|
Palantir Stock Jumps on S&P 500 Addition. Here’s Who Else Was Added.
|
|
Sep 9
|
Palantir Soars, Dell Pops As Big AI Plays Finally Get S&P 500 Nod
|
|
Sep 9
|
Palantir and Dell Will Join S&P 500—What You Need To Know
|
|
Sep 6
|
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
|
|
Sep 6
|
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
|
|
Jul 26
|
Bio-Rad Laboratories’ (BIO) Growth Tailwinds Are Delayed, Not Derailed
|
|
Jun 14
|
Is Bio-Rad Laboratories (BIO) a Lucrative Investment?
|
|
May 30
|
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
|
|
May 23
|
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
|
|
May 16
|
Q1 2024 OncoCyte Corp Earnings Call
|
|
May 10
|
Here's What Analysts Are Forecasting For Bio-Rad Laboratories, Inc. (NYSE:BIO) After Its First-Quarter Results
|
|
May 8
|
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
|
|
May 8
|
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 Bio Rad Laboratories Inc Earnings Call
|
|
May 7
|
Bio-Rad Laboratories Inc (BIO) Q1 2024 Earnings: Mixed Results Amid Market Challenges
|
|
May 7
|
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
|
|
May 7
|
Bio-Rad Reports First-Quarter 2024 Financial Results
|
|
May 1
|
Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
|
|
May 1
|
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
|